Literature DB >> 6227286

Action of the antitumor and antispermatogenic agent lonidamine on electron transport in Ehrlich ascites tumor mitochondria.

A Floridi, A L Lehninger.   

Abstract

The effect of lonidamine, an antispermatogenic and antitumor drug, on the oxygen consumption, ATPase activity, and redox state of the electron carriers of Ehrlich ascites tumor mitochondria has been studied. Lonidamine inhibits ADP- and uncoupler-stimulated respiration on various NAD- and FAD-linked substrates, but does not affect state 4 respiration. Experiments to determine its site of action showed that lonidamine does not significantly inhibit electron flow through cytochrome oxidase. Electron flow through site 2, the ubiquinone-cytochrome b-cytochrome c1 complex, also was unaffected by lonidamine, which failed to inhibit the oxidation of duroquinol. Moreover, inhibition of electron flow through site 2 was also excluded because of the inability of the N,N,N',N'-tetramethyl-p-phenylenediamine bypass to relieve the lonidamine inhibition of the oxidation of pyruvate + malate. The F0F1ATPase activity and vectorial H+ ejection are also unaffected by lonidamine. The inhibition of succinate oxidation by lonidamine was found to take place at a point between succinate and iron-sulfur center S3. Spectroscopic experiments demonstrated that lonidamine inhibits the reduction of mitochondrial NAD+ by pyruvate + malate and other NAD-linked substrates in the transition from state 1 to state 4. However, lonidamine does not inhibit reduction of added NAD+ by submitochondrial vesicles or by soluble purified NAD-linked dehydrogenases. These observations, together with other evidence, suggest that electron transport in tumor mitochondria is inhibited by lonidamine at the dehydrogenase-coenzyme level, particularly when the electron carriers are in a relatively oxidized state and/or when the inner membrane-matrix compartment is in the condensed state. The action of lonidamine in several respects resembles the selective inhibition of electron transport in tumor cells produced by cytotoxic macrophages (D. L. Granger and A. L. Lehninger (1982) J. Cell Biol. 95, 527).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6227286     DOI: 10.1016/0003-9861(83)90272-2

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  28 in total

1.  Individuation of subcellular targets of antitumor agents by ultrastructural methods.

Authors:  G Arancia
Journal:  Cytotechnology       Date:  1991-02       Impact factor: 2.058

2.  The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2006

3.  Quercetin, a fluorescent bioflavanoid, inhibits Trypanosoma brucei hexokinase 1.

Authors:  Heidi C Dodson; Todd A Lyda; Jeremy W Chambers; Meredith T Morris; Kenneth A Christensen; James C Morris
Journal:  Exp Parasitol       Date:  2010-11-11       Impact factor: 2.011

4.  Optical Redox Imaging of Lonidamine Treatment Response of Melanoma Cells and Xenografts.

Authors:  He N Xu; Min Feng; Kavindra Nath; David Nelson; Jeff Roman; Huaqing Zhao; Zhenwu Lin; Jerry Glickson; Lin Z Li
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

Review 5.  Adjudin--A Male Contraceptive with Other Biological Activities.

Authors:  Yan-Ho Cheng; Weiliang Xia; Elissa W P Wong; Qian R Xie; Jiaxiang Shao; Tengyuan Liu; Yizhou Quan; Tingting Zhang; Xiao Yang; Keyi Geng; Bruno Silvestrini; Chuen-Yan Cheng
Journal:  Recent Pat Endocr Metab Immune Drug Discov       Date:  2015

Review 6.  Interaction of oligomeric breast cancer resistant protein (BCRP) with adjudin: a male contraceptive with anti-cancer activity.

Authors:  Yan Ho Cheng; Pranitha Jenardhanan; Premendu P Mathur; Xiaojing Qian; Weiliang Xia; Bruno Silvestrini; Chuen Yan Cheng
Journal:  Curr Mol Pharmacol       Date:  2014       Impact factor: 3.339

7.  Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.

Authors:  G N Schwartz; B A Teicher; J P Eder; T Korbut; S A Holden; G Ara; T S Herman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 8.  Mechanism of antineoplastic activity of lonidamine.

Authors:  Kavindra Nath; Lili Guo; Bethany Nancolas; David S Nelson; Alexander A Shestov; Seung-Cheol Lee; Jeffrey Roman; Rong Zhou; Dennis B Leeper; Andrew P Halestrap; Ian A Blair; Jerry D Glickson
Journal:  Biochim Biophys Acta       Date:  2016-08-04

9.  (31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan.

Authors:  Kavindra Nath; David S Nelson; Andrew M Ho; Seung-Cheol Lee; Moses M Darpolor; Stephen Pickup; Rong Zhou; Daniel F Heitjan; Dennis B Leeper; Jerry D Glickson
Journal:  NMR Biomed       Date:  2012-06-29       Impact factor: 4.044

10.  Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.

Authors:  B A Teicher; T S Herman; J Tanaka; B Dezube; A Pardee; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.